1. Sweden Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
CombiGene AB (publ)

CombiGene AB (publ)

COMBI.ST
CombiGene AB (publ)SE flagStockholm Stock Exchange
2.47
SEK
-0.10
- -
48.91MMarket Cap
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
TTM
Revenue per Share
- -
3.67
0.01
- -
- -
4.85
1.35
0.28
0.02
0.02
Basic EPS, GAAP
-8.08
-10.95
-9.47
-5.93
-3.29
1.21
-0.31
-1.8
-2.27
-2.27
Free Cash Flow per Basic Share
-8.35
-11.64
-0.46
-7.27
-4.3
1.27
-0.84
-1.55
-1.51
-1.51
Dividend per Share
0.5
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-6.98
-29.94
-24.6
-17
2.56
0.06
0.05
0.05
-2.22
-2.22
Tangible Book Value per Share
2.66
6.46
13.55
-1.56
5.3
7.9
6.72
5.05
3.61
3.61
Basic Weighted Avg Shares
1
1
1
3
9
17
20
20
20
20
Sales/Revenue/Turnover
- -
3
- -
- -
- -
84
27
6
- -
- -
Operating Margin (%)
- -
-298.6
-162,408.09
- -
- -
24.5
-72.89
-696.25
-14,484.05
-14,484.05
Depreciation Expense
- -
- -
- -
1
2
3
3
3
13
13
Net Income, GAAP
-9
-9
-13
-18
-29
21
-6
-36
-45
-45
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
-298.6
-161,380.65
- -
- -
24.95
-23.06
-643.31
-13,766.26
-13,765.95
Working Capital
3
5
19
-5
47
137
133
99
71
71
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
4
7
20
20
71
158
152
116
72
72
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
175.31
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
175.31
-621.87
-3,602.31
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Jun'24
Sep'24
Dec'24
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
20
20
20
Market Capitalization
57
55
47

Working Capital

FRC

•

in mil. unless spec.
Jun'24
Sep'24
Dec'24
Total Current Assets
85
78
75
Cash, Cash Equivalents & STI
84
77
74
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
6
5
4
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
61.5%
-38.54%
Free Cash Flow
- -
-34.67%
-2.34%
Net Income, GAAP
- -
54.26%
25.83%
Sales/Revenue/Turnover
- -
- -
-94.12%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
11
5
5
-16
27
2023
2
2
1
1
6
2024
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
-0.14
0.23
0.2
- -
-0.31
2023
-0.74
-0.32
-0.42
-0.32
-1.8
2024
-0.72
-0.38
-0.45
-0.71
-2.27

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
Peter Ekolind
Full Time Employees
9
Sector
Healthcare
Industry
Biotechnology
Address
Agavagen 52A Lidingö Sweden 181 55
IPO Date
May 25, 2015
Website
combigene.com
Similar Companies
Qyuns Therapeutics Co., Ltd. (2509.HK)
NeuBase Therapeutics, Inc. (NBSE)
Blueprint Medicines Corporation (BPMC)
Angion Biomedica Corp. (ANGN)
Nuformix plc (NFX.L)
Novo Nordisk A/S (NOVO-B.CO)
Business
CombiGene AB (publ) develops gene therapies targeting severe neurological disorders with high unmet medical needs, including drug-resistant focal epilepsy and chronic pain conditions. The company focuses on adeno-associated virus-based gene therapy candidates such as CG01 for epilepsy seizure suppression via neuropeptide Y expression; the COZY program, comprising COZY01 (peptide-based) and COZY02 (gene therapy) targeting the PICK1 receptor for chronic pain; and earlier efforts like CGT2 for lipodystrophy in collaboration with Lipigon Pharmaceuticals AB. Operations center on preclinical research, proof-of-concept validation, and out-licensing to partners for clinical development and commercialization; CombiGene sources assets from academic collaborations including Lund University and University of Copenhagen, serving patient markets in neurology and biotechnology globally from headquarters in Stockholm, Sweden (visiting address: Skeppsbron 38, SE-111 30 Stockholm), founded in 1990. In October 2021, CombiGene entered an exclusive global licensing agreement with Spark Therapeutics (Roche subsidiary) for CG01, which Spark terminated in October 2023 amid strategic prioritization. In October 2024, the company sharpened focus on gene therapy by terminating the CG01 epilepsy program, implementing cost reductions projected to save SEK 57 million through Q2 2026, and extending liquidity; by January 2025, CombiGene discontinued all research activities and collaborations including the Zyneyro pain program agreement and divested its stake in CCRM Nordic AB, shifting toward strategic investments in cash-flow positive opportunities and partner evaluations for remaining assets. The company lists on Nasdaq First North Growth Market (ticker: COMBI.ST) with Certified Adviser FNCA Sweden AB.